Exhibit 10.4.3





 


AMENDMENT
NO. 3 TO LICENSE AND SUPPLY AGREEMENT


 


This
AMENDMENT NO. 3 TO LICENSE AND SUPPLY AGREEMENT (this  “Amendment”) is made and entered into as of January 31,
2014 and shall become effective upon the closing of an IPO (as defined in the License Agreement). This Amendment amends that certain
License and Supply Agreement dated as of May 23, 2013, as amended from time to time (the “License Agreement”),
by and between Ruthigen, Inc., a Delaware corporation (“Ruthigen”) and Oculus Innovative Sciences, Inc., a
Delaware corporation (“Oculus”). Capitalized terms used and not defined herein shall have the meanings given
to them in the License Agreement.


 


WHEREAS,
Section 15.13 of the License Agreement provides that the License Agreement may be amended, if such amendment is reduced to writing
and signed by the authorized officers of both Parties to the License Agreement;


 


WHEREAS,
the Parties entered into Amendment No. 1 to License Agreement on October 9, 2013;


 


WHEREAS,
the Parties entered into Amendment No. 2 to License Agreement on November 6, 2013 (“Amendment No. 2”).


 


WHEREAS,
the Parties now wish to amend certain sections of the License Agreement as set forth herein.


 


NOW,
THEREFORE, in consideration of the mutual covenants, agreements and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Parties agree as follows:


 


1.  
        Amendment to Definition of “Field”. The definition of “Field”
in the License Agreement is hereby deleted in its entirety and the following language is inserted in lieu thereof:


 


 “Field”
means all Invasive uses in humans.  “Field” does not include dermatologic uses or uses related to the Indications.


 


2.    
      Deletion of Definition of “Out of Pocket Cost”. The definition of Out
of Pocket Cost in the License Agreement is hereby deleted in its entirety. This deletion has no effect on other references to
 “out of pocket cost” in the License Agreement.


 


3.       
   Deletion of Section 2.2. The text of Sections 2.2(a), (b) and (c) of the License Agreement is hereby
deleted in its entirety and the words  “Intentionally Omitted” are inserted in lieu thereof.


 


4.      
    Amendment to Section 2.4(a)(iii). Section 2.4(a)(iii) of the License Agreement is hereby
amended to delete in its entirety subsection (iii) and to insert the following language in lieu thereof:


 


 “(iii)
the worldwide making, having made, use, sale, offer to sell, having sold and import by Oculus of products and services related
to the Indications;”


 


5.      
    Amendment to Section 2.4(b). Section 2.4(b) is hereby amended to delete the words  “,
prior to Ruthigen’s exercise of the OOS Option, if ever,” in the clause beginning  “products and services
related to the Indications” and to retain the words  “inside the Territory.”


 




    	1



    	 



    

 


6.      
    Amendment to Section 6.13(a). The introductory lead-in language and Section 6.13(a) of the
License Agreement, as amended by Amendment No. 2, is hereby deleted in its entirety and the following language is inserted in
lieu thereof:


 


 “6.13
Manufacturing Equipment. Ruthigen may, at any time upon at least 90 days’ prior written notice to Oculus, purchase
one or more units of Manufacturing Equipment, at Ruthigen’s discretion. Oculus shall deliver the Manufacturing Equipment
to Ruthigen, at Ruthigen’s expense, within 90 days of Oculus’ receipt of payment from Ruthigen therefor. However, if
there is a third party delay for parts or other components needed to make the Manufacturing Equipment, Oculus may deliver such
Manufacturing Equipment beyond the 90 days by the amount of time such part or component was delayed.


 


		(a)	Ruthigen shall purchase the Manufacturing Equipment at Oculus’s Cost of Goods plus 20% (the
 “Equipment Purchase Price”').”



 


7.       
   Amendment to Section 6.13(d). Section 6.13(d) of the License Agreement is hereby deleted in its
entirety and the following language is inserted in lieu thereof:


 


 “Oculus
shall have the right to repurchase the Manufacturing Equipment (i) upon a Change in Control of Ruthigen involvingan acquiring
Third Party that sells hypochlorous-acid products, or that competes with Oculus as a manufacturer of hypochlorous acid formulations
or processes involving electrolysis, unless in either case such Third Party is headquartered in Japan, or (ii) if Ruthigen takes
any of the actions listed in Section 14.2(b), or any of the situations listed in 14.2(b) shall have occurred, in any case, at no
cost.”


 


8.       
   Amendment to Section 6.13(e). Section 6.13(e) of the License Agreement is hereby deleted in its
entirety and the following language is inserted in lieu thereof:


 


 “Ruthigen
shall have the right to purchase Oculus’ entire inventory of Manufacturing Equipment (i) upon a Change in Control of Oculus
involving an acquiring Third Party that sells hypochlorous-acid products, or that competes with Ruthigen as a manufacturer of hypochlorous
acid formulations or processes involving electrolysis, unless in either case such Third Party is headquartered in Japan, or (ii)
if Oculus takes any of the actions listed in Section 14.2(b), or any of the situations listed in 14.2(b) shall have occurred, in
any case, at the replacement cost of such Manufacturing Equipment.”


 


9.    
      Amendment to Milestones. The table listing the Milestone Events and Milestone
Payments under the License Agreement, which is set forth in Section 7.1 of the License Agreement, is hereby deleted in its
entirety and the following table listing the Milestone Events and Milestone Payments under the License Agreement is inserted
in lieu thereof:


 


	 	 	Milestone Event	 	Milestone Payment	 
	1.	 	Upon completion of last patient enrollment in Ruthigen's Phase 1/2 clinical study	 	$	1,500,000	 
	2.	 	Upon completion of last patient enrollment in Ruthigen's first pivotal clinical study	 	$	1,500,000	 
	3.	 	Upon completion of Ruthigen’s first meeting with the FDA following completion of Ruthigen’s first pivotal clinical trial	 	$	3,000,000	 
	4.	 	Upon first patient enrollment in Ruthigen’s second pivotal clinical trial	 	$	2,000,000	 



 




    	2



    	 



    

 


10.         Amendment
to Section 14.2(b) Section 14.2(b) of the License Agreement is hereby deleted and the following language is inserted in lieu
thereof:


 


 “(b)
In the event that one of the Parties, (i) voluntarily commences any proceeding or voluntary filing of any petition by such Party
seeking relief under any bankruptcy, insolvency, receivership or similar law; (ii) consents to the institution of, or fails to
contest in a timely and appropriate manner and cause to be dismissed within 90 days, any involuntary petition or any involuntary
filing of the type described in clause (i) above; (iii) ceases to do business or takes any action for its winding up, liquidation
or dissolution; (iv) makes a general assignment for the benefit of such Party’s creditors; (v) is generally unable to pay
debts as they become; (vi) is adjudicated bankrupt or insolvent under any bankruptcy, insolvency, receivership or similar law;
or (vii) has appointed a trustee, receiver, liquidator or statutory manager in respect of such Party or all or any substantial
part of such Party’s assets or properties, the other Party shall be entitled to terminate this Agreement (including any license
granted to such Party) immediately without notice.”


 


11.         Development
and Commercialization Plan. The Parties acknowledge and agree that Ruthigen’s Development and Commercialization shall
not include any activities related to dermatological uses or uses related to the Indications. Any references to the OOS Option,
the Indications or any product or service outside the definition of Invasive in the Development and Commercialization Plan are
hereby deleted.


 


12.         Effect
of this Amendment. Except as specifically amended as set forth herein, each term and condition of the License Agreement shall
continue in full force and effect.


 


13.         Governing
Law. This Amendment shall be governed by and construed in accordance with the laws in force in the State of California, without
giving effect to the choice of laws provisions thereof.


 


14.         Counterparts;
Facsimile Signatures. This Amendment may be executed or consented to in counterparts, each of which shall be deemed an original
and all of which taken together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile
or electronically and, upon such delivery, the facsimile or electronically transmitted signature will be deemed to have the same
effect as if the original signature had been delivered to the other party.


 


[Remainder
of page intentionally left blank.]






 


 






    	3



    	 



    

 


IN
WITNESS WHEREOF, the Parties have caused this Amendment No. 3 to License Agreement to be duly executed and delivered by their
proper and duly authorized officers as of the day and year first above written.


 


	OCULUS	 	RUTHIGEN
	 	 	 
	OCULUS INNOVATIVE SCIENCES INC.	 	RUTHIGEN, INC.
	 	 	 
	By:	/s/  James Schutz	 	By: 	/s/ Hojabr Alimi
	Name:  	James Schutz	 	Name:  	Hojabr Alimi
	Title: 	Chief Executive Officer	 	Title: 	Chief Executive Officer
	Date:	January 31, 2014	 	Date: 	January 31, 2014